Molecular and Cellular Mechanisms of Fingolimod Action
Abstract
The data on the mechanism of action, efficacy and safety of the drug fingolimod are presented. Further study of the molecular, biochemical and cellular mechanisms of action of pharmacological regulators of phospholipid mediators' signal transduction is an important basis for developing new immunomodulators and antitumor agents.
References
1. NDA 02257-FDA approved labeling text for Gilenya (fiingolimod) capsules / September 21, 2010.http://www.accessdata.fda.gov.
2. Billich A., Bonmancin F., Devay P. et al. Phosphorilation of the immunomodulatory drug FTY720 by sphingosine kinase. J Biol Chem 2003; 278: 47408-47415.
3. Paugh S.W., Payne S.G., Barbour S.E. et al. The immunosupressant FTY720 is phosphorilated by sphingosine kinase type 2. FEBS Lett 2003; 554: 189-193.
4. Spiegel S., Milstein S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Res Mol Cell Biol 2003; 4: 397-407.
5. Ishii I., Fukushima N., Ye X., Chung J. Lysophospholipid receptors: signalling and biology. Annu Rev Biochem 2004; 73: 321-354.
6. Schwab S.R., Pereira J.P., Matloullian M. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption S1P gradients. Science 2005; 309: 1735-1739.
7. Oo M.L., Thangada S., Wu M.-T. et al. Immunosupressive and anti-angiogenic sphingosine-1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation by internalized S1P1 receptors. Nat Chem Biol 2009; 5: 428-434.
8. Kappos L., Radue E.-W., O., Konnor P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 2010; 362: 387-401.
9. Cohen J.A., Barkhof F., Comi G. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 2010; 362: 402-415.
10. Dehmel T., Opgenoorth B., Hartung H. et al. The effect of fingolimod on peripheral blood mononuclear cell phenotypes: a prospective study (P02.122). Neurology 2012, 78 (Meeting abstracts 1): P02.122.
11. Sehr T., Hainke U., Thomas K. et al. Differential immunological changes in peripheral and CNS compartments during fingolimod therapy in MS (P02.087). Neurology 2012, 78 (Meeting abstracts 1): P02.087.
12. Darlington P., Ouamara N., Stonebridge I. et al. Fingolimod treatment in multiple sclerosis increases the ability of circulating γδ T cells to regulate pro-inflammatory Th1 and Th2 T cell responses (S31.003). Neurology 2012, 78 (Meeting abstracts 1): S31.003.
13. Cohen J.A., Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.
14. Kipp M., Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scller 2012; 18: 258-262.
15. Thomas K., Sehr T., Hainke U. et al. Differential effects of natalizumab and fingolimod on the innate immune system of MS patients (P04.125). Neurology 2012, 78. (Meeting abstracts 1): P04.125.
16. Lorvik K.B., Bogen B., Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119: 2176-2177.
17. Cannon R.E., Pearle J.C., Hawkins B.T. et al. Targeting blood-brain barrier sphingolipid signalling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci. USA 2012; 109: 15930-15935.
18. Di Marco J.P., O'Connor P., Cohen J.A. et al. First dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830). Mult Scler 2010; 16: Suppl 10.
19. Kennedy P.C., Zhu R., Huang T. et al. Characterization of a sphingosine-1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 2011; 338: 879-889.
Review
For citations:
Nikitin A.V. Molecular and Cellular Mechanisms of Fingolimod Action. Antibiot Khimioter = Antibiotics and Chemotherapy. 2013;58(11-12):38-42. (In Russ.)
Views:
320
Email this article 